Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioVaxys Technology's total inventories for the quarter that ended in Jul. 2025 was €0.00 Mil. BioVaxys Technology's average total inventories from the quarter that ended in Apr. 2025 to the quarter that ended in Jul. 2025 was €0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. BioVaxys Technology's Net-Net Working Capital per share for the quarter that ended in Jul. 2025 was €-0.11.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioVaxys Technology (FRA:5LB0) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
BioVaxys Technology's Net-Net Working Capital Per Share for the quarter that ended in Jul. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BioVaxys Technology's Inventory to Revenue for the quarter that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
BioVaxys Technology Total Inventories Related Terms
BioVaxys Technology Total Inventories Historical Data
* Premium members only.
The historical data trend for BioVaxys Technology's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
BioVaxys Technology (FRA:5LB0) has a Total Inventories of €0.00 Mil as of Jul. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for BioVaxys Technology and its competitors.
Is BioVaxys Technology's Total Inventories too high?
BioVaxys Technology's current Total Inventories is €0.00 Mil.
How does BioVaxys Technology's Total Inventories compare to BPTH and AZTR?
BioVaxys Technology's Total Inventories of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for BioVaxys Technology and its competitors. BioVaxys Technology's current Total Inventories is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (FRA:5LB0) has a current Total Inventories of €0.00 Mil. The current Total Inventories is €0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For BioVaxys Technology (FRA:5LB0), the current Total Inventories is €0.00 Mil as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5LB0 has been successfully added to your 
